Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
40 participants
INTERVENTIONAL
2021-10-01
2022-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Role of Non-Selective Beta-Adrenergic Blocker in Severe TBI
NCT06870370
Beta Blockade in in Traumatic Brain Injury
NCT02957331
Beta Blocker Use In Traumatic Brain Injury Based On The High-Sensitive Troponin T Status
NCT04508244
Using Propranolol in Traumatic Brain Injury to Reduce Sympathetic Storm Phenomenon
NCT03401515
Early Propranolol After Traumatic Brain Injury: Phase II
NCT01202110
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Parameters assessment:
* Length of ICU stay
* Length of total hospital stay
* CT scan to exclude another intracranial hemorrhage or increase in hemorrhage
* Functional status will be assessed using the GCS
* Hemodynamic data ( bl.p / hr )
* Crystalloid volume that patient need in 24h
* Mortality rate
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
beta blocker
Will be given Propranolol 1mg in 10 ml distilled water intravenous every 6 hours for 48 hours
Propranolol
intravenous propranolol for case patients
placebo
Will be given normal saline 10 ml every 6 hours for 48 hours
Saline
intravenous saline for placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Propranolol
intravenous propranolol for case patients
Saline
intravenous saline for placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Abbreviated Injury Scale (AIS) \>3
* Length stay in ICU \>48 h
Exclusion Criteria
* Asthmatic patient
* COPD
* History of smoking
* Any cardiac problems eg: ( heart failure or HB )
* pheochromocytoma
* Pregnant patient
* Length stay \<48h
* Death within 48 h of admission
* Patient who previously received any beta blocker at home.
* Symptomatic Bradycardia \<60 b/m (sick sinus syndrome)
* Hemodynamic unstable patients
16 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Menoufia University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
mostafa saieed fahim mansour
lecturer
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
mostafa f mansour, MD
Role: PRINCIPAL_INVESTIGATOR
Menoufia University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faculty of Medicine, University Hospitals
Shibīn al Kawm, Menoufia, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2/2021ANESTH-4
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.